Drug Trial Radar · NCT04562766
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
232
Actual
Start
Dec 14, 2020
Primary completion
Jan 15, 2025
Study completion Sep 2, 2026
Sponsor
- Lead sponsor
- Principia Biopharma, a Sanofi CompanyIndustry
- Sponsor type
- Industry
- First posted
- Sep 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a randomized, double-blind study of rilzabrutinib in patients with persistent or chronic ITP, with an average platelet count of \<30,000/μL (and no single platelet count \>35,000/μL) on two counts at least 5 days apart in the 14 days before treatment begins. Patients received rilzabrutinib or placebo 400mg twice daily. For each patient, the study lasted up to 60 weeks from the start of the Screening Period to the End of Study (EOS) visit. This included Screening (up to 4 weeks) through a 12 to 24-week Blinded Treatment Period followed by a 28-week Open-Label Period. Followed by a 4-week post dose follow-up. For adult participants, the maximum duration of the long-term extension (LTE) period was 12 months from the date of the last adult participant to enter the LTE. For pediatric participants, the maximum duration of the LTE period was 12 months from the date of the last pediatric participant to enter the LTE.
Conditions
- Immune Thrombocytopenia
Interventions
RilzabrutinibDrug
400mg Caplet
PlaceboDrug
400mg Caplet
Primary outcomes
What the sponsor says the trial is designed to measure.
- DB Period: Percentage of Participants With Durable Platelet Response Per Guidance in Regions Except European Union and United KingdomTime frame: Up to 24 weeks
- DB Period: Percentage of Participants With Durable Platelet Response Per Guidance in European Union and United KingdomTime frame: Up to 24 weeks
Locations
155 sites in 26 countries. Site status is shown where the registry gives one.
University of Southern California_Investigational Site Number 84024
Los Angeles, California
UCSF Benioff Children's Hospital San Francisco_Investigational Site Number 84020
San Francisco, California
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center_Investigational Site Number 84037
Torrance, California
The Oncology Institute of Hope and Innovation_Investigational Site Number 84031
Whittier, California
Children's Hospital Colorado_Investigational Site Number 84025
Aurora, Colorado
IMMUNOe International Research Centers_Investigational Site Number 84028
Centennial, Colorado
ASCLEPES Research Centers_Investigational Site Number 84023
Weeki Wachee, Florida
Children's Healthcare of Atlanta_Investigational Site Number 84034
Atlanta, Georgia
Rush University Medical Center_Investigational Site Number 84029
Chicago, Illinois
University of Louisville - James Graham Brown Cancer Center_Investigational Site Number 84033
Louisville, Kentucky
Massachusetts General Hospital Site Number : 84038
Boston, Massachusetts
Montefiore Medical Center_Investigational Site Number 84032
The Bronx, New York
University Hospitals Cleveland Medical Center Site Number : 84036
Cleveland, Ohio
Cleveland Clinic_Investigational Site Number 84026
Cleveland, Ohio
The Children's Hospital of Philadelphia (CHOP)_Investigational Site Number 84027
Philadelphia, Pennsylvania
University of Utah-Huntsman Cancer Institute_Investigational Site Number 84035
Salt Lake City, Utah
University of Washington Medical Centre Site Number : 84041
Seattle, Washington
Investigational Site Number : 3209
Corrientes, Argentina
Investigational Site Number : 3208
San Juan, Argentina
Investigational Site Number : 3206
Capital Federal, Buenos Aires, Argentina
Investigational Site Number : 3211
La Plata, Buenos Aires, Argentina
Investigational Site Number : 3205
Córdoba, Córdoba Province, Argentina
Investigational Site Number : 3607
Kogarah, New South Wales, Australia
Investigational Site Number : 3608
Westmead, New South Wales, Australia
Investigational Site Number : 3611
Brisbane, Queensland, Australia
Investigational Site Number : 3609
Adelaide, South Australia, Australia
Investigational Site Number : 3606
Frankston, Victoria, Australia
Investigational Site Number : 3610
Perth, Western Australia, Australia
Investigational Site Number : 4005
Graz, Austria
Investigational Site Number : 4004
Leoben, Austria
Investigational Site Number : 4001
Linz, Austria
Investigational Site Number : 4003
Steyr, Austria
Investigational Site Number : 4002
Vienna, Austria
CEMEC Oncologica do Brasil Site Number : 7606
Belém, Brazil
HEMORIO - Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti Site Number : 7609
Rio de Janeiro, Brazil
Hospital do Servidor Publico Estadual de Sao Paulo Site Number : 7607
São Paulo, Brazil
Hospital Sao Rafael Instituto D'Or da Bahia Site Number : 7608
Salvador, Estado de Bahia, Brazil
Uniao Oeste Paranaense de Estudos e Combates ao Cancer Site Number : 7610
Cascavel, Paraná, Brazil
Hospital De Clinicas De Porto Alegre Site Number : 7605
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Santa Marcelina Site Number : 7611
São Paulo, São Paulo, Brazil
Showing 40 of 155 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.